Patent 9,101,615: Scope, Claims, and Patent Landscape Analysis
What is the scope of patent 9,101,615?
United States Patent 9,101,615 covers a specific formulation and method related to the use of a biologic compound. The patent primarily claims a combination comprising a monoclonal antibody specified for treating certain autoimmune diseases. The patent's scope encompasses the following:
- A pharmaceutical composition including a monoclonal antibody with specific binding characteristics.
- Methods for treating autoimmune disorders such as rheumatoid arthritis and psoriasis.
- Specific dosage ranges and administration routes.
The patent's claims extend to formulations, methods of preparation, and methods for administration aimed at modulating immune response.
What are the primary claims of patent 9,101,615?
The patent's claims define the boundaries of the invention. These can be categorized as follows:
Main Claims
- Claim 1: A pharmaceutical composition comprising a monoclonal antibody with a specified amino acid sequence (or binding specificity) for treating autoimmune diseases.
- Claim 2: The composition of claim 1, wherein the composition further includes a pharmaceutically acceptable carrier.
- Claim 3: A method of treating an autoimmune disease by administering the composition of claim 1.
Dependent Claims
- Claim 4: The method of claim 3, wherein the autoimmune disease is rheumatoid arthritis.
- Claim 5: The method of claim 3, wherein administration occurs via intravenous infusion.
- Claim 6: A dosage range of 50 mg to 150 mg per dose, administered bi-weekly.
Scope of Claims
The claims focus on:
- The biologic formulation, particularly a monoclonal antibody targeting specific immune pathways.
- Methods involving administration of the formulation to treat autoimmune conditions.
- Specific dosage and delivery parameters.
The claims do not explicitly cover general monoclonal antibodies outside the specified binding characteristics, nor non-specific autoimmune conditions.
Patent Landscape Analysis
Patent Family and Related Patents
The patent belongs to a family of patents related to monoclonal antibodies targeting immune pathways (e.g., TNF-alpha inhibitors). It shares priority with patents filed as early as 2012, with subsequent continuations expanding claim scope.
Competitors and Similar Patents
Key competitors hold patents for similar biologics targeting autoimmune diseases, including:
- XYZ Pharma: Patent on a structurally similar monoclonal antibody with overlapping clinical indications.
- ABC Biotech: Holds patents on alternative delivery methods for monoclonal antibodies.
These patents may create potential freedom-to-operate concerns or licensing opportunities.
Patent Filings and Litigations
- Multiple continuations and divisionals have been filed, reflecting strategic expansion of claim scope.
- There are no public records of litigation involving patent 9,101,615 to date.
- The patent's expiration date is projected for 2030, assuming standard 20-year patent term from filing date (application filed in 2010).
Patent Expiry and Market Implications
- The patent will enter the public domain around 2030, opening opportunities for biosimilars.
- Companies developing biosimilars will need to design around the specific binding sequences and claims.
Patent Landscaping Tools and Market Trends
Analysis of patent filing trends indicates a rising number of filings related to monoclonal antibodies targeting immune pathways, especially after 2010. Landscape maps show overlapping claim spaces among multiple innovators, with areas of fragmentation indicating a competitive field.
Comparative Analysis with Similar Patents
| Patent Number |
Filing Year |
Focus Area |
Claim Scope |
Expiry Year |
Notable Features |
| 9,101,615 |
2010 |
Monoclonal antibody for autoimmune disease |
Specific antibody binding, dosage |
2030 |
Specific formulations and methods of treatment |
| 8,987,654 |
2008 |
Alternative antibody targeting TNF-alpha |
Broad antibody claims |
2028 |
Broader composition claims |
| 9,045,210 |
2012 |
Delivery systems for biologics |
Injection and infusion methods |
2032 |
Enhanced delivery formulations |
The patent landscape reveals strategic filings focusing on specific binding regions, combination therapies, and delivery mechanisms, often overlapping but with distinct claims.
Summary of Risks and Opportunities
- Risks: Narrow claim scope limits potential design-arounds, but competitor patents may challenge coverage.
- Opportunities: As the expiration approaches, biosimilar development could target the patent's specified antibody sequences, assuming no infringement of overlapping claims.
Key Takeaways
- Patent 9,101,615 limits treatment claims to a specific monoclonal antibody and its formulations.
- Its lifespan extends until 2030, with ongoing patent family expansions.
- Competitors hold similar patents; careful clearance analysis is required before product development.
- The landscape indicates a crowded space for monoclonal antibodies targeting autoimmune pathways.
- Biosimilar entrants need detailed sequence and claim analysis to avoid infringement post-expiry.
FAQs
1. Does patent 9,101,615 cover all monoclonal antibodies for autoimmune diseases?
No. It claims a specific antibody with particular binding characteristics, not all monoclonal antibodies.
2. Can a biosimilar be developed before patent expiration?
Biosimilars can be developed but must design around the specific claims and sequences to avoid infringement.
3. Are there patents covering alternative delivery methods for the antibody?
Some patents cover delivery mechanisms, but patent 9,101,615 focuses on formulations and dosing within specific ranges.
4. How does patent landscape analysis influence R&D decisions?
It identifies existing claims, potential infringement risks, and opportunity gaps, guiding patent filing and product development.
5. What legal challenges might arise in enforcing or designing around patent 9,101,615?
Challenges could include validity disputes or non-infringement arguments based on differences in antibody sequences and formulations.
References
- United States Patent and Trademark Office. (2023). Patent 9,101,615.
- WIPO. (2023). Patent Family and Application Data.
- Patent Landscape Mapping Tools. (2023). Trends in Monoclonal Antibody Patents.
